Published in:
01-10-2013 | Opinion Paper
Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications
Authors:
Fredrik B. Thorén, Harald Anderson, Örjan Strannegård
Published in:
Cancer Immunology, Immunotherapy
|
Issue 10/2013
Login to get access
Abstract
Late divergence of survival curves of treated patients and controls is commonly seen in successful cancer immunotherapy trials. Although late survival curve divergence may be caused by a delayed action of therapy, it may also be related to early effects of the treatment. We suggest that late survival divergence most often reflects a specific benefit of therapy for patients who suffer from a comparatively slow progression of disease. The occurrence of delayed survival curve divergence has important implications for the statistical analysis of immunotherapy trials. Thus, it leads to non-proportional hazard ratios that make commonly used statistical tests, e.g., the logrank test, suboptimal. It is therefore suggested that the statistical analysis of immunotherapy trials primarily should be based on a test that compares the survival curves at or after a prespecified, fixed, late time point.